A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

Masanori Sawada; Daisuke Sugiyama; Takenobu Nii; Katsuhiro Konno; Hardy T.S. Kagimoto

doi:10.1016/j.clinthera.2018.10.001

A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

Masanori Sawada, Daisuke Sugiyama, Takenobu Nii, Katsuhiro Konno, Hardy T.S. Kagimoto

Leukemia

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.

Original language	English (US)
Pages (from-to)	1801-1806
Number of pages	6
Journal	Clinical Therapeutics
Volume	40
Issue number	11
DOIs	https://doi.org/10.1016/j.clinthera.2018.10.001
State	Published - Nov 2018

Keywords

cell medicine
iPS cells
regenerative medicine
somatic stem cells

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/j.clinthera.2018.10.001

Cite this

@article{ae1335dd1eb0489a839d7399e4699301,

title = "A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine",

abstract = "Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.",

keywords = "cell medicine, iPS cells, regenerative medicine, somatic stem cells",

author = "Masanori Sawada and Daisuke Sugiyama and Takenobu Nii and Katsuhiro Konno and Kagimoto, {Hardy T.S.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = nov,

doi = "10.1016/j.clinthera.2018.10.001",

language = "English (US)",

volume = "40",

pages = "1801--1806",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Excerpta Medica",

number = "11",

}

TY - JOUR

T1 - A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

AU - Sawada, Masanori

AU - Sugiyama, Daisuke

AU - Nii, Takenobu

AU - Konno, Katsuhiro

AU - Kagimoto, Hardy T.S.

PY - 2018/11

Y1 - 2018/11

N2 - Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.

AB - Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.

KW - cell medicine

KW - iPS cells

KW - regenerative medicine

KW - somatic stem cells

UR - http://www.scopus.com/inward/record.url?scp=85055911658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055911658&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2018.10.001

DO - 10.1016/j.clinthera.2018.10.001

M3 - Article

C2 - 30396514

AN - SCOPUS:85055911658

SN - 0149-2918

VL - 40

SP - 1801

EP - 1806

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 11

ER -

A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this